Valproate

What it is

Valproate is a small branched fatty acid used as a medicine. It is sold in several chemical forms - valproic acid, sodium valproate, and divalproex sodium, which dissociates to the valproate ion in the gut - and all deliver the same active valproate ion. It is a prescription-only medicine, available as tablets, delayed- and extended-release tablets, sprinkle capsules, syrup and an intravenous form. It carries one of the most consequential boxed warnings in medicine, covering liver failure, fetal harm and pancreatitis.

What the research says

The evidence is good that it works and equally good that it is dangerous in pregnancy. It is among the more effective drugs for generalised epilepsy - in the SANAD II randomised trial levetiracetam failed to prove non-inferiority to it - and a network meta-analysis of 72 double-blind trials places it among the drugs effective for acute mania. A Cochrane review found it reduces migraine frequency, with a number needed to treat of 4 and a number needed to harm of 7 to 14. Against that, prospective registry data put major congenital malformations at 9.9% after first-trimester valproate monotherapy, and children exposed in the womb had measurably lower IQ at age 6. For agitation in dementia, for neuropathic pain and, once open trials are excluded, for schizophrenia, the evidence does not support it.

Evidence grade: Well established.

How it works

Drug class: Broad-spectrum antiseizure medication and mood stabiliser; a branched short-chain fatty acid. Divalproex sodium is a 1:1 coordination compound of sodium valproate and valproic acid

Honestly, it is not settled. The label states plainly that the mechanisms by which valproate works have not been established, and suggests its antiseizure activity may relate to raised brain levels of the inhibitory neurotransmitter GABA. Divalproex sodium itself is a delivery form that splits into the valproate ion in the gut. (Source 1)

Boxed warning

WARNING: LIFE THREATENING ADVERSE REACTIONS See full prescribing information for complete boxed warning . Hepatotoxicity, including fatalities, usually during the first 6 months of treatment. Children under the age of two years and patients with mitochondrial disorders are at higher risk. Monitor patients closely, and perform serum liver testing prior to therapy and at frequent intervals thereafter ( 5.1 ) Fetal Risk, particularly neural tube defects, other major malformations, and decreased IQ ( 5.2 , 5.3 , 5.4 ) Pancreatitis, including fatal hemorrhagic cases ( 5.5 )

(Source 2)

What it is used for

• A network meta-analysis of 72 double-blind randomised trials in 16,442 adults found valproate among the drugs that beat placebo for treatment response and for improvement in mania symptoms, though only four antipsychotics had better acceptability than placebo. The label notes efficacy was established in three-week trials and that long-term use in mania was not established. Evidence: established. (Source 3)
• In SANAD II, an open-label randomised trial of 520 people, levetiracetam did not meet non-inferiority against valproate for 12-month remission (hazard ratio 1.19, 95% CI 0.96 to 1.47) and valproate was superior in the per-protocol analysis. The authors concluded levetiracetam was neither clinically effective nor cost-effective by comparison. Evidence: established. (Source 4)
• A 2013 Cochrane review of 10 trials found divalproex sodium more than doubled the proportion of responders against placebo (risk ratio 2.18, 95% CI 1.28 to 3.72, number needed to treat 4), with numbers needed to harm of 7 to 14 for clinically important adverse events. The label contraindicates this use in pregnancy and in women of childbearing potential not using effective contraception. Evidence: established. (Source 5)
• A Cochrane review of 26 trials in 2,184 people found adding valproate to an antipsychotic improved clinical response (risk ratio 1.31, 95% CI 1.16 to 1.47, low-quality evidence), but the effect disappeared once open-label trials were excluded, and the authors noted the evidence was entirely based on open trials. Sedation was significantly more frequent. Evidence: not-supported. (Source 6)
• A 2018 Cochrane review of five placebo-controlled trials in 430 people concluded valproate preparations are probably ineffective for agitation in dementia and carry a higher rate of adverse effects (odds ratio 2.02, 95% CI 1.30 to 3.14). Evidence: not-supported. (Source 7)
• A 2011 Cochrane review found only three small trials, none in fibromyalgia, and concluded there is insufficient evidence to support valproate as a first-line treatment for neuropathic pain, with more adverse events than placebo. Evidence: not-supported. (Source 8)

Interactions

• Carbapenem antibiotics (ertapenem, imipenem, meropenem) (case reports): These antibiotics can drop valproate blood levels to below the useful range and cause seizures to return. The mechanism is not well understood. The label advises frequent monitoring of valproate levels after a carbapenem is started. (Source 9)
• Aspirin, including over-the-counter doses (pharmacokinetic study): Aspirin displaces valproate from plasma proteins and inhibits its metabolism, so the free, active fraction rises sharply. In a study of six children on antipyretic aspirin doses the free fraction increased four-fold, which can produce toxicity at an unchanged total blood level. (Source 9)
• Lamotrigine (pharmacokinetic study): Valproate roughly triples how long lamotrigine stays in the body, and serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported when the two are combined. Lamotrigine doses are reduced accordingly. (Source 10)
• Topiramate (label): The combination has been linked to hyperammonaemia and encephalopathy - raised blood ammonia with confusion or lethargy - and to hypothermia. (Source 11)
• Cannabidiol (CBD), which is also widely sold as a food supplement (label): Taking cannabidiol with valproate has been associated with rises in the liver enzymes ALT and AST. This matters particularly because valproate already carries a boxed warning for liver failure. (Source 11)
• L-carnitine supplements (theoretical): Valproate depletes carnitine, which is part of how it raises blood ammonia and produces toxic metabolites. L-carnitine supplementation has been recommended and used empirically to counter valproate liver toxicity, and is used as rescue therapy after overdose. The quantitative work behind dosing is a computer model, not a randomised trial, so this is mechanistic rather than outcome evidence. (Source 12)
• Alcohol and other sedatives (label): Valproate causes central nervous system depression and this is worse when combined with another depressant such as alcohol. The label's counselling section tells patients not to drive or use dangerous machinery until they know whether the drug makes them drowsy. (Source 13)
• Food (label): No food blocks or boosts valproate meaningfully, but the label notes that people who get gastrointestinal irritation may do better taking it with food, or by building the dose up slowly. Delayed-release tablets must be swallowed whole, not crushed or chewed. (Source 14)
• Estrogen-containing hormonal contraceptives and methotrexate (label): These can change valproate clearance; estrogen-containing contraceptives may increase it, lowering valproate levels. The label groups them with aspirin and carbapenems as reasons to monitor valproate concentrations. (Source 11)

Stopping it

• Valproate taken to prevent major seizures must not be stopped abruptly: the label warns of the strong possibility of precipitating status epilepticus, a prolonged seizure that threatens life. (Source 15)
• Among people with epilepsy who were seizure-free and then withdrew their medication, an individual-participant meta-analysis of 1,769 patients found relapse in 46%, and 9% still had seizures in their last year of follow-up - meaning lasting control was not always regained. Predictors of relapse included how long the epilepsy lasted before remission, how long the person had been seizure-free before withdrawing, and an epileptiform EEG before withdrawal. (Source 16)
• The same analysis identified which features predict relapse, which is what withdrawal decisions are built on; the authors note the main limitation was the absence of a control group that continued treatment. (Source 16)
• If pancreatitis is diagnosed the boxed warning directs that valproate ordinarily be discontinued; cases have been reported both shortly after starting and after years of use, and some progressed rapidly to death. (Source 17)

What goes wrong

In the same dementia review, valproate caused more adverse effects than placebo and possibly more serious adverse events. (Source 7)

• Systematic review, Low certainty.
• Size: 381 participants across three trials for adverse effects; 228 across two trials for serious adverse events.
• Who: People with dementia and agitation.
• How long: Three to six weeks.
• Result: Adverse effects odds ratio 2.02 (95% CI 1.30 to 3.14), low-quality evidence; serious adverse events odds ratio 4.77 (95% CI 1.00 to 22.74), very low quality. More frequent on valproate: sedation, nausea, vomiting, diarrhoea and urinary tract infections.
• Funding: not stated.

A meta-analysis of three studies showed that there may have been a higher rate of adverse effects among valproate-treated participants than among controls (odds ratio (OR) 2.02, 95% CI 1.30 to 3.14; 381 participants, 3 studies, low-quality evidence).

Major congenital malformations occurred in 9.9% of pregnancies exposed to valproate monotherapy, the highest of eight commonly used antiseizure medicines, and the risk rose with dose. (Source 18)

• Cohort study, Moderate certainty.
• Size: 9,840 pregnancies exposed to the eight most used antiseizure medicines, within 10,121 monotherapy-exposed pregnancies in 8,483 women.
• Who: Women with epilepsy aged 14 to 55 enrolled before the pregnancy outcome was known, in more than 40 countries (EURAP registry), offspring followed to one year.
• How long: Enrolment June 1999 to October 2022.
• Result: Valproate 153/1,549 (9.9%, 95% CI 8.5% to 11.5%) versus lamotrigine 110/3,584 (3.1%, 95% CI 2.5% to 3.7%) and levetiracetam 33/1,325 (2.5%, 95% CI 1.8% to 3.5%). Malformation prevalence rose significantly with increasing valproate dose. This is an observational cohort, so the comparison is an association, not a randomised one.
• Funding: not stated.

MCMs occurred in 153 of 1549 pregnancies for valproate (9.9%; 95% CI, 8.5%-11.5%)

Children exposed to valproate in the womb had lower IQ at age 6 than children exposed to carbamazepine, lamotrigine or phenytoin, with a dose-response relationship. (Source 19)

• Cohort study, Moderate certainty.
• Size: 305 mothers and 311 children; 224 children completed 6 years of follow-up.
• Who: Children of pregnant women with epilepsy on antiepileptic monotherapy, enrolled 1999-2004 at 25 centres in the UK and USA; assessors masked.
• How long: Followed to age 6 years.
• Result: Age-6 IQ 97 (95% CI 94 to 101) after valproate versus carbamazepine 105 (102-108, p=0.0015), lamotrigine 108 (105-110, p=0.0003) and phenytoin 108 (104-112, p=0.0006). Higher valproate dose correlated with lower IQ (r=-0.56, p<0.0001). Observational, adjusted for maternal IQ, drug type, standardised dose, gestational age and periconceptional folate.
• Funding: not stated.

Multivariate analysis of all children showed that age-6 IQ was lower after exposure to valproate (mean 97, 95% CI 94-101) than to carbamazepine (105, 102-108; p=0·0015), lamotrigine (108, 105-110; p=0·0003), or phenytoin (108, 104-112; p=0·0006).

Fatal valproate-associated liver failure is not confined to young children on multiple drugs; 26 adult cases had been reported by 1999, half of them without any underlying metabolic or liver disease. (Source 20)

• Case series, Very low certainty.
• Size: One index case plus 26 adult cases from the literature.
• Who: Adults over 17 years; three of the 26 were on valproate monotherapy; ages 17 to 62.
• How long: Time to first symptom ranged from 7 days to 6 years of treatment.
• Result: Twelve of 26 affected adults had no underlying disease or a clearly non-metabolic, non-hepatic disease. The index patient, a 29-year-old with Friedreich's ataxia, died of liver failure and bronchopneumonia two months after starting valproate. Case reports cannot give a rate.
• Funding: not stated.

Twenty-six adult patients (>17 years) with VPA-associated fatal hepatotoxicity have been reported in the literature. Of the 26 adult patients, three were receiving VPA monotherapy.

In placebo-controlled epilepsy add-on trials, valproate caused far more nausea, vomiting, tremor, somnolence and abdominal pain than placebo. (Source 21)

• Official position, Moderate certainty.
• Size: 77 on Depakote versus 70 on placebo.
• Who: Adults in the placebo-controlled trial of adjunctive therapy for complex partial seizures (patients also on other antiepileptic drugs)
• How long: Trial duration not stated in the label excerpt.
• Result: Nausea 48% vs 14%, headache 31% vs 21%, vomiting 27% vs 7%, asthenia 27% vs 7%, somnolence 27% vs 11%, tremor 25% vs 6%, dizziness 25% vs 13%, abdominal pain 23% vs 6%, anorexia 12% vs 0%. In the acute mania trials, nausea 22% vs 15%, somnolence 19% vs 12%, dizziness 12% vs 4%, vomiting 12% vs 3%; only vomiting reached statistical significance.
• Funding: not stated (manufacturer label text)

Table 3. Adverse Reactions Reported by ≥ 5% of Patients Treated with Depakote During Placebo-Controlled Trial of Adjunctive Therapy for Complex Partial Seizures Body System/Reaction Depakote (n = 77) % Placebo (n = 70) % Body as a Whole Headache 31 21 Asthenia 27 7 Fever 6 4 Gastrointestinal System Nausea 48 14 Vomiting 27 7 Abdominal Pain 23 6 Diarrhea 13 6 Anorexia 12 0 Dyspepsia 8 4 Constipation 5 1 Nervous System Somnolence 27 11 Tremor 25 6 Dizziness 25 13

Antiseizure medicines as a class roughly double the risk of suicidal thinking or behaviour against placebo, an absolute increase from 0.24% to 0.43%. (Source 22)

• Meta-analysis, Moderate certainty.
• Size: 27,863 drug-treated and 16,029 placebo-treated patients across 199 placebo-controlled trials of 11 antiepileptic drugs.
• Who: Patients treated for epilepsy, psychiatric indications and other conditions.
• How long: Median treatment duration 12 weeks.
• Result: Adjusted relative risk 1.8 (95% CI 1.2 to 2.7); incidence 0.43% on drug versus 0.24% on placebo, an absolute difference of about 0.19 percentage points. By indication the label reports 3.4 versus 1.0 events per 1,000 for epilepsy and 8.5 versus 5.7 per 1,000 for psychiatric indications.
• Funding: not stated (US FDA pooled analysis as reproduced in the manufacturer label)

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo.

Among people with epilepsy who had become seizure-free and then withdrew their antiseizure medication, 46% relapsed. (Source 16)

• Systematic review, Moderate certainty.
• Size: 1,769 patients from 10 studies included in the meta-analysis, from 45 studies and 7,082 patients identified.
• Who: Children and adults with epilepsy who were seizure-free and started withdrawing antiseizure medication; non-selected and selected populations.
• How long: Median follow-up 5.3 years (IQR 3.0-10.0, maximum 23 years)
• Result: Relapse in 812 of 1,769 (46%); 136 of 1,455 (9%) still had seizures in their last year of follow-up. Main limitation stated by the authors: no control group that continued treatment.
• Funding: independent (Epilepsiefonds)

Relapse occurred in 812 (46%) of 1769 patients; 136 (9%) of 1455 for whom data were available had seizures in their last year of follow-up, suggesting enduring seizure control was not regained by this timepoint.

What the evidence supports

In newly diagnosed generalised or unclassifiable epilepsy, levetiracetam failed to prove non-inferiority to valproate for 12-month remission, and valproate was superior in the per-protocol analysis. (Source 4)

• Randomized trial, Moderate certainty.
• Size: 520 participants (260 per arm) at 69 UK centres.
• Who: Adults and children aged 5 years or older with two or more unprovoked generalised or unclassifiable seizures; median age 13.9 years, 65% male.
• How long: Recruited 2013-2016, followed for a further 2 years.
• Result: Intention-to-treat hazard ratio 1.19 (95% CI 0.96 to 1.47) against a non-inferiority margin of 1.314. Adverse reactions in 96 (37%) on valproate and 107 (42%) on levetiracetam. Open-label design, so neither participants nor investigators were blinded.
• Funding: independent (UK National Institute for Health Research Health Technology Assessment Programme)

Levetiracetam did not meet the criteria for non-inferiority in the ITT analysis of time to 12-month remission (HR 1·19 [95% CI 0·96-1·47]); non-inferiority margin 1·314.

Valproate is among the drugs that beat placebo for response in acute bipolar mania, but it is not among those with better acceptability than placebo. (Source 3)

• Meta-analysis, Moderate certainty.
• Size: 16,442 participants across 72 double-blind randomised controlled trials of 23 drugs.
• Who: Adults with acute bipolar mania, mean age 39.55 years, 50.93% male.
• How long: Mean study duration 3.96 (SD 2.39) weeks.
• Result: Valproate was among 13 drugs that outperformed placebo for response (56 trials, 14,503 participants) and for improvement in mania symptoms; only aripiprazole, olanzapine, quetiapine and risperidone had better all-cause discontinuation than placebo.
• Funding: not stated.

Compared with the placebo, aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, tamoxifen, valproate, and ziprasidone outperformed response to treatment (N = 56, n = 14503)

Divalproex sodium more than doubled the proportion of migraine responders against placebo, with a number needed to treat of 4. (Source 5)

• Systematic review, Moderate certainty.
• Size: 10 trials; 542 participants in the divalproex-versus-placebo responder analysis.
• Who: Adults with episodic migraine.
• How long: Trial durations varied; review search to January 2013.
• Result: Risk ratio 2.18 (95% CI 1.28 to 3.72), number needed to treat 4 (95% CI 2 to 11). Sodium valproate reduced headache frequency by about four headaches per 28 days versus placebo (mean difference -4.31, 95% CI -8.32 to -0.30, two trials, 63 participants). No significant difference versus flunarizine or propranolol; topiramate 50 mg slightly better than valproate 400 mg (mean difference -0.90, 95% CI -1.58 to -0.22).
• Funding: not stated.

Data from four trials (542 participants) showed that divalproex sodium (a stable combination of sodium valproate and valproic acid in a 1:1 molar ratio) more than doubled the proportion of responders relative to placebo (RR 2.18; 95% CI 1.28 to 3.72; NNT 4; 95% CI 2 to 11).

What the evidence does not support

Valproate preparations are probably ineffective for agitation in dementia on the primary behavioural outcome. (Source 23)

• Systematic review, Moderate certainty.
• Size: 430 participants across five randomised placebo-controlled trials; 202 in the pooled BPRS analysis.
• Who: People with dementia and agitation; mean doses 480 to 1000 mg/day.
• How long: Three to six weeks.
• Result: Total Brief Psychiatric Rating Scale mean difference 0.23 (95% CI -2.14 to 2.59) and BPRS agitation factor -0.67 (95% CI -1.49 to 0.15), both moderate-quality evidence. Functional ability was probably slightly worse on valproate (Physical Self-Maintenance Scale mean difference 1.19, 95% CI 0.40 to 1.98).
• Funding: not stated.

They found that there was probably little or no effect of valproate treatment over six weeks (total BPRS: mean difference (MD) 0.23, 95% confidence interval (CI) -2.14 to 2.59; 202 participants, 2 studies; BPRS agitation factor: MD -0.67, 95% CI -1.49 to 0.15; 202 participants, 2 studies).

Adding valproate to an antipsychotic in schizophrenia appeared to improve response, but the effect disappeared when unblinded trials were excluded. (Source 6)

• Systematic review, Low certainty.
• Size: 2,184 participants across 26 randomised trials; 1,049 in the response analysis.
• Who: People with schizophrenia or schizophrenia-like psychoses, all trials testing valproate as an add-on to antipsychotics; most trials small, unblinded and short.
• How long: Mostly short-term; review search to March 2016.
• Result: Clinical response risk ratio 1.31 (95% CI 1.16 to 1.47), I2 = 12%, low-quality evidence - removed in a sensitivity analysis excluding open trials. Sedation risk ratio 1.38 (95% CI 1.07 to 1.79).
• Funding: not stated.

Adding valproate to antipsychotic treatment resulted in more clinically significant response than adding placebo to antipsychotic drugs (14 RCTs, n = 1049, RR 1.31, 95% CI 1.16 to 1.47, I2 = 12%, low-quality evidence). However, this effect was removed after excluding open RCTs in a sensitivity analysis.

There is insufficient evidence to support valproate for neuropathic pain, and no trials at all in fibromyalgia. (Source 8)

• Systematic review, Very low certainty.
• Size: Three trials: 84 participants in diabetic neuropathy and 45 in post-herpetic neuralgia.
• Who: Adults with chronic neuropathic pain; no fibromyalgia studies found.
• How long: Eight or 12 weeks.
• Result: Efficacy reported only for study completers, insufficient data for pooled analysis. More adverse events than placebo including nausea, drowsiness and abnormal liver function tests; one participant withdrew with serious derangement of liver enzymes.
• Funding: not stated.

There is insufficient evidence to support the use of valproic acid or sodium valproate as a first-line treatment for neuropathic pain.

Where the research disagrees

Whether valproate's effectiveness in generalised epilepsy justifies its use in girls and women who could become pregnant

• SANAD II investigators (2021), An open-label randomised controlled trial of 520 participants in which the main alternative drug failed to prove non-inferiority: "Compared with valproate, levetiracetam was found to be neither clinically effective nor cost-effective. For girls and women of child-bearing potential, these results inform discussions about benefit and harm of avoiding valproate." (Source 4)
• US labelling for DEPAKOTE (AbbVie, revised May 2025), A regulatory position in a boxed warning, resting on malformation and neurodevelopmental data: "Valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable." (Source 24)
• EURAP registry investigators (2024), A prospective observational cohort of 9,840 monotherapy-exposed pregnancies: "Prevalence of MCMs was higher with phenytoin, valproate, carbamazepine, and phenobarbital, and dose dependent for the latter 3 ASMs." (Source 18)

How much

• Reference intake: There is no reference intake for a prescription medicine; dosing is set by the prescriber. As a position, the US label gives an initial 750 mg daily in divided doses for mania, 10 to 15 mg/kg/day for complex partial seizures and 15 mg/kg/day for absence seizures, and 250 mg twice daily for migraine prophylaxis (DailyMed label for DEPAKOTE, AbbVie, revised May 2025). (Source 25)
• Upper limit: No upper limit is set by a nutrition body. The label's stated maximum recommended dosage is 60 mg/kg/day for mania and for seizures, and 1,000 mg/day for migraine prophylaxis; the label adds that no recommendation about safety above 60 mg/kg/day can be made (DailyMed label for DEPAKOTE, AbbVie, revised May 2025). (Source 25)
• Studied: SANAD II advised initial maintenance doses of 500 mg twice daily of valproate for people aged 12 or older, and 25 mg/kg/day for children aged 5 to 12. (Source 4)
• Studied: Cochrane migraine trials compared sodium valproate 400 mg against topiramate 50 mg in one pooled analysis; the review covered sodium valproate and divalproex sodium at the doses used in 10 trials. (Source 5)
• Studied: Dementia agitation trials pooled by Cochrane used mean doses of 480 mg/day to 1,000 mg/day for three to six weeks. (Source 7)
• Studied: The label reports that in placebo-controlled acute mania trials patients were dosed to a trough plasma concentration between 50 and 125 mcg/mL, with the usually accepted therapeutic range in epilepsy given as 50 to 100 mcg/mL. (Source 26)

A common belief, and what the research shows

The belief: Valproate's pregnancy risk is the only serious problem with it; otherwise it is an old, well-tolerated drug.

What the research shows: The boxed warning names three separate life-threatening problems, not one. On liver injury it states: "Hepatic failure resulting in fatalities has occurred in patients receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment." On pancreatitis: "Cases of life-threatening pancreatitis have been reported in both children and adults receiving valproate." And a published review of adult cases found that "Twelve of the 26 affected adults had no underlying disease or a clearly nonmetabolic and non-hepatic disease" - so fatal liver injury is not confined to small children with metabolic disease. Common effects are also substantial: in placebo-controlled add-on epilepsy trials nausea was 48% versus 14% and tremor 25% versus 6%.

Questions and answers

What is it?

Valproate is a small branched fatty acid used as a medicine for seizures, bipolar mania and migraine prevention. It is sold as valproic acid, sodium valproate or divalproex sodium; divalproex splits into the valproate ion in the gut, so all forms deliver the same active substance. It is prescription-only. (Source 1)

What does it do in the body?

Nobody is certain. The manufacturer's own label says the mechanisms by which valproate produces its effects have not been established, and suggests its action in epilepsy may involve raised brain levels of GABA, the main inhibitory neurotransmitter. In practice it dampens excessive electrical activity in the brain and stabilises mood in mania. (Source 1)

Is it good or bad for you?

Both, depending sharply on who takes it. It is one of the more effective drugs for generalised epilepsy and works for acute mania and migraine prevention. But taken during pregnancy it causes major congenital malformations in about one pregnancy in ten and lowers children's IQ, which is why its boxed warning restricts use in anyone who could become pregnant. It also carries boxed warnings for fatal liver failure and for life-threatening pancreatitis, and it does not work for agitation in dementia or neuropathic pain. (Source 24)

How do you get more of it?

Only by prescription. As a position, the label starts mania treatment at 750 mg daily in divided doses, epilepsy at 10 to 15 mg/kg/day, and migraine prevention at 250 mg twice daily, with a stated maximum of 60 mg/kg/day for mania and seizures. Doses are titrated against response and blood levels. This is not a recommendation about dose. (Source 25)

If it is harmful, what reduces it?

It is cleared from the body once stopped, but stopping it is not something to do alone. The label warns that antiepileptic drugs given to prevent major seizures must not be stopped abruptly because of the strong possibility of precipitating status epilepticus. Where valproate must come off - pregnancy, suspected liver injury, pancreatitis - that is managed by the prescriber, usually by tapering and substituting another drug. For hyperammonaemia linked to carnitine depletion, L-carnitine has been used empirically. (Source 15)

Why might someone be low in it or missing it?

Blood levels can fall below the useful range for several reasons. Carbapenem antibiotics cause a clinically significant drop and can let seizures return. Enzyme-inducing drugs such as phenytoin, carbamazepine, phenobarbital and ritonavir can roughly double valproate clearance, and estrogen-containing hormonal contraceptives can increase it too. People may also be taken off the drug deliberately - because of pregnancy or pregnancy planning, liver or pancreatic injury, thrombocytopenia, or side effects. (Source 9)

Which whole foods contain it or feed it?

Does not apply in the usual sense: no whole food contains valproate and no diet produces it. Food matters only for tolerance - the label notes that people who get stomach irritation may do better taking it with food or building the dose up slowly. Delayed-release tablets must be swallowed whole rather than crushed or chewed. (Source 14)

What happens if you do not have it?

Nothing happens from lacking the drug itself; the body does not need it. What matters is the condition it was treating. In people whose epilepsy was controlled and who then withdrew antiseizure medication, 46% relapsed over a median 5.3 years, and 9% were still having seizures in their final year of follow-up - so control was not always regained. Stopping abruptly in someone taking it to prevent major seizures risks status epilepticus. (Source 16)

How can you test for it?

A blood valproate level is measured routinely. The label gives a usually accepted therapeutic range of 50 to 100 mcg/mL for epilepsy, and notes that thrombocytopenia becomes significantly more likely above trough levels of 110 mcg/mL in women and 135 mcg/mL in men. The test has a real limitation the label states itself: because valproate binds plasma proteins in a non-linear, concentration-dependent way, the total serum level is not a reliable index of the active drug - which is also why aspirin, by displacing it from protein, can cause toxicity at an apparently normal total level. Liver tests and platelet counts are monitored alongside, and ammonia is measured if someone becomes unexplainedly lethargic or confused. (Source 1)

References

1. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - Clinical Pharmacology, Mechanism of Action and Pharmacodynamics. 2026. Read the source
2. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - boxed warning (highlights of prescribing information). 2026. Read the source
3. Molecular Psychiatry. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. 2022. PMID 34642461, DOI 10.1038/s41380-021-01334-4. Read the source
4. The Lancet. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. 2021. PMID 33838758, DOI 10.1016/S0140-6736(21)00246-4. Read the source
5. Cochrane Database of Systematic Reviews. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults (Cochrane systematic review). 2013. PMID 23797677, DOI 10.1002/14651858.CD010611. Read the source
6. Cochrane Database of Systematic Reviews. Valproate for schizophrenia (Cochrane systematic review). 2016. PMID 27884042, DOI 10.1002/14651858.CD004028.pub4. Read the source
7. Cochrane Database of Systematic Reviews. Valproate preparations for agitation in dementia (Cochrane systematic review). 2018. PMID 30293233, DOI 10.1002/14651858.CD003945.pub4. Read the source
8. Cochrane Database of Systematic Reviews. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults (Cochrane systematic review). 2011. PMID 21975791, DOI 10.1002/14651858.CD009183.pub2. Read the source
9. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - Drug Interactions, aspirin and carbapenem antibiotics. 2026. Read the source
10. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - Drug Interactions, lamotrigine. 2026. Read the source
11. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - Drug Interactions (highlights). 2026. Read the source
12. European Journal of Pharmaceutical Sciences. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation. 2023. PMID 36740101, DOI 10.1016/j.ejps.2023.106399. Read the source
13. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - Patient Counseling Information, CNS Depression. 2026. Read the source
14. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - General Dosing Advice, G.I. Irritation. 2026. Read the source
15. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - Dosage and Administration, discontinuation. 2026. Read the source
16. The Lancet Neurology. Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis. 2017. PMID 28483337, DOI 10.1016/S1474-4422(17)30114-X. Read the source
17. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - boxed warning, Pancreatitis. 2026. Read the source
18. JAMA Neurology. Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy (EURAP registry). 2024. PMID 38497990, DOI 10.1001/jamaneurol.2024.0258. Read the source
19. The Lancet Neurology. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. 2013. PMID 23352199, DOI 10.1016/S1474-4422(12)70323-X. Read the source
20. Epilepsia. Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adults. 1999. PMID 10403231, DOI 10.1111/j.1528-1157.1999.tb00814.x. Read the source
21. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - Adverse Reactions, adjunctive therapy for complex partial seizures. 2026. Read the source
22. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - Warnings and Precautions, Suicidal Behavior and Ideation. 2026. Read the source
23. Cochrane Database of Systematic Reviews. Valproate preparations for agitation in dementia (Cochrane systematic review) - primary efficacy outcome. 2018. PMID 30293233, DOI 10.1002/14651858.CD003945.pub4. Read the source
24. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - boxed warning, Fetal Risk. 2026. Read the source
25. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - Dosage and Administration. 2026. Read the source
26. AbbVie Inc., via DailyMed (US FDA structured product label). DEPAKOTE (divalproex sodium) delayed-release tablets - Dosage and Administration, plasma concentrations. 2026. Read the source